Vulnerability, social value and the equitable sharing of benefits from research: beyond the placebo and access debates

The vulnerability of research participants is a critical topic for the 2024 revision of the Declaration of Helsinki, with the proposal to include "social value. " However, this proposal has been withdrawn and the relationship between the two concepts has not been clarified. This paper attempts to clarify: (1) the recent reform for the ethical inclusion of vulnerable study participants to promote diversity; (2) the social value, prerequisite for everyone, especially for those who are vulnerable and the most in need; (3) the requirements for promoting the inclusion of vulnerable participants, in particular the review of the norms for placebo-controlled trials and post-trial access; (4) finally, the direction of research ethics reform to achieve social value and equitable global health.

Authors

Institutions

Publication Details

Journal
Frontiers in Medicine
Published
2024-09-17
DOI
https://doi.org/10.3389/fmed.2024.1432267
Citations
7
Primary Topic
Ethics in Clinical Research
Type
article
Field-Weighted Citation Impact
3.80

Funders

Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

Vulnerability, social value and the equitable sharing of benefits from research: beyond the placebo and access debates

Kotone Matsuyama, Dirceu Bartolomeu Greco, Chieko Kurihara, Ames Dhai et al.
7 citations
Frontiers in Medicine
Ethics in Clinical Research
3.80
article

Vulnerability, social value and the equitable sharing of benefits from research: beyond the placebo and access debates

Kotone Matsuyama, Dirceu Bartolomeu Greco, Chieko Kurihara, Ames Dhai, Varvara Baroutsou
article en
7 citations

Abstract

The vulnerability of research participants is a critical topic for the 2024 revision of the Declaration of Helsinki, with the proposal to include "social value. " However, this proposal has been withdrawn and the relationship between the two concepts has not been clarified. This paper attempts to clarify: (1) the recent reform for the ethical inclusion of vulnerable study participants to promote diversity; (2) the social value, prerequisite for everyone, especially for those who are vulnerable and the most in need; (3) the requirements for promoting the inclusion of vulnerable participants, in particular the review of the norms for placebo-controlled trials and post-trial access; (4) finally, the direction of research ethics reform to achieve social value and equitable global health.

Frontiers in MedicineVol. 11
Universidade Federal de Minas Gerais (BR), University of the Witwatersrand (ZA), Kanagawa Dental University (JP), International Pharmaceutical Federation (NL), Nippon Medical School (JP)
Associação Médica Brasileira
Reduced inequalities
Openalex Percentile: Top 6%
Ethics in Clinical Research
3.80
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Vulnerability, social value and the equitable sharing of benefits from research: beyond the placebo and access debates — Kotone Matsuyama, Dirceu Bartolomeu Greco, et al. · Frontiers in Medicine (2024) | TGRS Research Map | TGRS